Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Siarhei Kandabarau"'
Autor:
Maksim Klimiankou, Murat Uenalan, Siarhei Kandabarau, Rainer Nustede, Ingeborg Steiert, Sabine Mellor-Heineke, Cornelia Zeidler, Julia Skokowa, Karl Welte
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
High frequency of acquired CSF3R (colony stimulating factor 3 receptor, granulocyte) mutations has been described in patients with severe congenital neutropenia (CN) at pre-leukemia stage and overt acute myeloid leukemia (AML) or myelodysplastic synd
Externí odkaz:
https://doaj.org/article/6a14cb3c6da849de9b0a3dafd9831e50
Autor:
Carolin Sauter-Meyerhoff, Regina Bohnert, Pascale Mazzola, Viktoria Stühler, Siarhei Kandabarau, Florian A. Büttner, Stefan Winter, Lisa Herrmann, Steffen Rausch, Jörg Hennenlotter, Falko Fend, Marcus Scharpf, Arnulf Stenzl, Stephan Ossowski, Jens Bedke, Matthias Schwab, Elke Schaeffeler
Publikováno v:
Cancers
Cancers; Volume 13; Issue 24; Pages: 6221
Cancers, Vol 13, Iss 6221, p 6221 (2021)
Cancers; Volume 13; Issue 24; Pages: 6221
Cancers, Vol 13, Iss 6221, p 6221 (2021)
Simple Summary Survival rates in metastatic renal cell carcinoma (RCC) are still low despite novel therapies available. Thus, knowledge of molecular characteristics of distant metastases is important for personalized treatment strategies. Therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0e7a5f579be592e4f55b438a8095c41
http://europepmc.org/articles/PMC8699544
http://europepmc.org/articles/PMC8699544
Autor:
Peter Fritz, Matthias Schwab, Werner Schroth, Tanja Fehm, Hiltrud Brauch, Jörg Kumbrink, Thomas E. Mürdter, Diethelm Wallwiener, Florian Büttner, Thomas Kirchner, Peter A. Fasching, Georg Sauer, David Allen Henderson, Siarhei Kandabarau, Reiner Hoppe, Stephen F. Madden, Yuqi Ren, Heather Ann Brauer
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 26(24)
Purpose: Patients with estrogen receptor– and/or progesterone receptor–positive, early breast cancer benefit from hormonal treatment, yet high global death burdens due to high prevalence and long-term recurrence risk call for biomarkers to guide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8e238edba6a46c87b72a4d3852aab4b
https://pubmed.ncbi.nlm.nih.gov/33008814
https://pubmed.ncbi.nlm.nih.gov/33008814
Autor:
Charlotte M. Niemeyer, Perihan Mir, Azadeh Zahabi, Cornelia Zeidler, Malte U Ritter, Tim Ripperger, Masoud Nasri, Siarhei Kandabarau, Anna Solovyeva, Benjamin Dannenmann, Benedikt Oswald, Maksim Klimiankou, Doris Steinemann, Patricia Arreba-Tutusaus, Jehan Mardan, Nico Lachmann, Julia Skokowa, Miriam Erlacher, Karl Welte, Thomas Moritz, Martina Konantz, Frederic Stein, Tatsuya Morishima, Claudia Lengerke
Publikováno v:
Cell Stem Cell. 28:906-922.e6
Severe congenital neutropenia (CN) is a pre-leukemic bone marrow failure syndrome that can evolve to acute myeloid leukemia (AML). Mutations in CSF3R and RUNX1 are frequently observed in CN patients, although how they drive the transition from CN to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee8d74d7ca2676af9a5525f490abdab
https://doi.org/10.1016/j.stem.2021.03.023
https://doi.org/10.1016/j.stem.2021.03.023
Autor:
Olga Klimenkova, Sabine Mellor-Heineke, Elisa Reinel, Karl Welte, Murat Uenalan, Cornelia Zeidler, Maksim Klimiankou, Julia Skokowa, Siarhei Kandabarau
Publikováno v:
Blood. 127:2638-2641
To the editor: Congenital neutropenia (CN) and cyclic neutropenia (CyN) are rare genetic disorders of hematopoiesis predominantly caused by ELANE mutations.[1][1][⇓][2]-[3][3] Due to overlaps in their genetic profiles, CyN can be distinguished from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8ade9168a79df173d20970685c298dec
https://doi.org/10.1182/blood-2015-12-685784
https://doi.org/10.1182/blood-2015-12-685784
Autor:
Heather E. Cunliffe, Balkees Abderrahman, Stefan Winter, V. Craig Jordan, Siarhei Kandabarau, Hiltrud Brauch, Reiner Hoppe, Werner Schroth, Ping Fan
Publikováno v:
Cancer Research. 80:144-144
Disruption of estrogen signaling with tamoxifen or aromatase inhibitors (AI) is the clinical standard for the treatment of estrogen receptor-positive breast cancer, yet resistance to antiestrogen therapies is inevitable. The long-term E2-deprived bre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68f0fca2513983f3b590f4bd77c7f8af
https://doi.org/10.1158/1538-7445.am2020-144
https://doi.org/10.1158/1538-7445.am2020-144
Autor:
Florian Büttner, Carolin Meyerhoff, Siarhei Kandabarau, Stefan Winter, Steffen Rausch, Arnulf Stenzl, Falko Fend, Christopher Schroeder, Peter Bauer, Per Hoffmann, Markus M. Nöthen, Jens Bedke, Matthias Schwab, Elke Schaeffeler
Publikováno v:
Cancer Research. 79:2529-2529
Renal cell carcinoma (RCC) accounts for 5% in men and 3% in women of all oncological diagnoses worldwide (Capitanio et al., Eur Urol 2018). In 0.7-4.7% of patients both kidneys are affected by cancer. Although hereditary forms of RCC do exist (VHL di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7b63b01ae708d5d67d5e5c778b21141
https://doi.org/10.1158/1538-7445.am2019-2529
https://doi.org/10.1158/1538-7445.am2019-2529
Autor:
Werner Schroth, Reiner Hoppe, Florian Büttner, Stefan Winter, Siarhei Kandabarau, Jörg Kumbrink, Heather A. Brauer, Peter Fritz, Matthias Schwab, Thomas Mürdter, Hiltrud Brauch
Publikováno v:
Cancer Research. 79:464-464
Estrogen (ER) and/or progesterone (PR) receptor-positive, early breast cancer benefits from targeted therapy via long-term estrogen deprivation. Valid treatment options include the selective ER modulator tamoxifen (TAM) that interferes with estrogen-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17d81cd27d65b46b85ba14d4af1e9bf8
https://doi.org/10.1158/1538-7445.am2019-464
https://doi.org/10.1158/1538-7445.am2019-464
Autor:
Reiner Hoppe, Siarhei Kandabarau, Ping Fan, V. Craig Jordan, Heather Cunliffe, Hiltrud B. Brauch
Publikováno v:
Cancer Research. 79:1689-1689
One third of breast cancer patients treated with Aromatase Inhibitors (AI) or Tamoxifen acquire resistance leading to disease recurrence and death. The clinically observed AI resistance is mimicked by in vitro models MCF-7:5C and MCF-7:2A that are su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65dec55f62f17455c7e91959d553befa
https://doi.org/10.1158/1538-7445.am2019-1689
https://doi.org/10.1158/1538-7445.am2019-1689
Autor:
Jens Bedke, Moreno Di Marco, Stefan Stevanovic, Joerg Hennenlotter, Matthias Schwab, Daniel J. Kowalewski, Elke Schaeffeler, Anna Reustle, Steffen Rausch, Linus Backert, Falko Fend, Stefan Winter, Arnulf Stenzl, Siarhei Kandabarau, Florian Büttner, Marcus Scharpf
Publikováno v:
Cancer Research. 78:5687-5687
Background Clear cell renal cell carcinoma (ccRCC) is the dominant subtype of renal cancer and frequently diagnosed at advanced disease stages. Cure of advanced and metastatic ccRCC is achieved only in rare cases with currently available therapies, c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80b47532f423999032043145d89838b4
https://doi.org/10.1158/1538-7445.am2018-5687
https://doi.org/10.1158/1538-7445.am2018-5687